About Us

GeneCentric Company Overview

GeneCentric Therapeutics is applying our proprietary rT(I)ME Explorer Platform to identify high resolution molecular subtypes and drug responder populations that enable the development of precision cancer drugs while improving patient outcomes. Our approach applies our rT(I)ME Explorer Platform to parse the complexity of the tumor and the immune microenvironment and overall tumor biology to generate response  signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers, or predictive response signatures, for immune-based, targeted and other cancer therapeutics. In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we can deploy the rT(I)ME Explorer Platform at all stages of the drug development cycle.


Kirk Beebe, PhD

Chief Scientific Officer

James M Davison, PhD

Senior Translational Genomics Scientist

Jeff Burdine

Sr. Director Information Technology

Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development

Felix Frueh, PhD

Genomics Application and Regulatory Expert Executive Partner, Opus Three Life Sciences

John Guo

John Guo, PhD

Senior Bioinformatics Scientist

LaTrell Jenkins

LaTrell Jenkins, MBA

Office Manager


Howard Kartstein

Director of Business Development

Myla Lai-Goldman, MD

Founder & Executive Chairperson

Greg Mayhew, DrPH

Director of Bioinformatics

Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President


Kirk Pappan, PhD, MBA

Director of Clinical Diagnostics

Joel Parker, PhD

Bioinformatics, RNA, and expression analysis expert Associate Professor, UNC-Chapel Hill

Paul Armistead, MD, PhD

Immunology, Hematologist and Antigen Expert Associate Professor of Medicine, UNC-Chapel Hill

Chenyqua Shepard, CPA

Chief Operating Officer

Jonathan Shepherd, PhD

Bioinformatics Scientist

Yoichiro Shibata, PhD

Senior Bioinformatics Scientist

Josh Uronis, PhD

Genomics Sequencing Operations Director

Benjamin Vincent, MD

Hematologist and Immunogenomics Expert Assistant Professor of Medicine, UNC-Chapel Hill

Myla Lai-Goldman, MD

Founder & Executive Chairperson

Arnold J. Levine, Phd


Ellen Lubman


Mike Milburn

Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay B. Thorp

General Partner, Hatteras Venture Partners

N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder